Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692548 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL268273 | 1.00 | KMT2A (0.48) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL1068706 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL30831586 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561971 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| Hydrochloric Acid SCHEMBL5561964 | 0.98 | KMT2A (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7244017 | 0.94 | ALDH1A1 (0.47) | KMT2AALDH1A1CYP3A4CYP2C19DPP4 | |
| SCHEMBL7342562 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL20543771 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 | |
| SCHEMBL21117726 | 0.86 | ALDH1A1 (0.48) | KMT2AALDH1A1DPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| US-11117930-B2 | Peptide inhibitors of transcription factor aggregation | ADRX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020189540-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | 中外製薬株式会社 | 2020-09-24 | — | — | WO | disclosed |
| CN-107903185-B | Preparation and application of novel eEF2K inhibitor | 四川大学 | 2020-05-26 | — | — | CN | disclosed |
| US-20200062804-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. | 2020-02-27 | — | — | US | disclosed |
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1042293-B9 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
| EP-1042293-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Amgen Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999032448-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | KMT2A 3516/4885ALDH1A1 557/4885CYP3A4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.